Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Immunomedics' LeukoScan

This article was originally published in The Gray Sheet

Executive Summary

Immunomedics' LeukoScan: Infectious disease imaging agent for use in detecting and diagnosing osteomyelitis (bone infection) involving long bones is cleared for marketing in European Union countries. The approved indication applies particularly to patients with diabetic foot ulcers. A biologic license application is pending at FDA to support use of the radiolabeled monoclonal antibody fragment for the same indication as that approved in the EU, as well as for use in detecting acute atypical appendicitis...

You may also be interested in...



Palatin's LeuTech Clinically Useful For Appendicitis Diagnosis - FDA Panel

Clinical management decisions on whether to use computed tomography (CT) or Palatin's LeuTech imaging agent for detecting appendicitis in patients with equivocal appendicitis likely will depend on an institution's level of expertise with each modality.

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT007593

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel